ERG rearrangement metastasis patterns in locally advanced prostate cancer
- PMID: 20018353
- PMCID: PMC2850965
- DOI: 10.1016/j.urology.2009.10.010
ERG rearrangement metastasis patterns in locally advanced prostate cancer
Abstract
Objectives: To interrogate multifocal prostate cancer (PCa) to determine its predilection for metastasis, using ERG rearrangement as marker of clonality. A hallmark of PCa is that distinct tumor foci may arise independently, which has important biological and clinical implications. Recent studies characterizing ERG-rearranged PCa possessing intrafocal homogeneity but interfocal heterogeneity support this hypothesis.
Methods: We studied 26 patients who underwent prostatectomy and lymphadenectomy with at least 2 distinct PCa foci and 1 lymph node (LN) metastasis. Each focus was assessed for size, Gleason score, ERG rearrangement, and TMPRSS2-ERG transcript.
Results: Fifteen of 26 cases exhibited interfocal homogeneity with regard to ERG rearrangement (ie, presence vs absence of ERG rearrangement). ERG rearrangement was present in all foci for 6 and absent in all foci for 9 cases. Two cases revealed interfocal heterogeneity with regard to rearrangement mechanism (ie, rearrangement through insertion or deletion). Eight of 26 cases revealed interfocal heterogeneity with regard to rearrangement status. In all cases with at least 1 ERG rearranged focus, we found the corresponding LN metastasis harboring an ERG rearrangement. Interestingly, in a subset of cases the rearrangement status in the LN did not correspond to size or Gleason score. All but 2 ERG rearranged foci had detectable TMPRSS2-ERG transcript levels.
Conclusions: When multifocal PCa demonstrates both ERG-positive and ERG-negative foci, the positive foci have a greater predilection for metastasis. Larger studies are needed to confirm the potential additional risk an ERG rearranged focus confers on the likelihood of disease progression.
Keywords: ERG rearrangements; TMPRSS2-ERG; metastatic; prostate cancer.
Copyright 2010 Elsevier Inc. All rights reserved.
Figures


Similar articles
-
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.Urology. 2007 Oct;70(4):630-3. doi: 10.1016/j.urology.2007.08.032. Urology. 2007. PMID: 17991527 Free PMC article.
-
The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.Hum Pathol. 2012 May;43(5):644-9. doi: 10.1016/j.humpath.2011.06.018. Epub 2011 Sep 19. Hum Pathol. 2012. PMID: 21937078 Free PMC article.
-
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.Mod Pathol. 2010 Apr;23(4):539-46. doi: 10.1038/modpathol.2009.193. Epub 2010 Jan 29. Mod Pathol. 2010. PMID: 20118910 Free PMC article.
-
ERG rearrangement is present in a subset of transition zone prostatic tumors.Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6. Mod Pathol. 2010. PMID: 20693982
-
The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.Dan Med J. 2016 Dec;63(12):B5319. Dan Med J. 2016. PMID: 27910803 Review.
Cited by
-
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.Am J Pathol. 2012 Nov;181(5):1573-84. doi: 10.1016/j.ajpath.2012.07.030. Epub 2012 Sep 27. Am J Pathol. 2012. PMID: 23022210 Free PMC article.
-
Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.Eur J Histochem. 2025 Feb 11;69(1):4172. doi: 10.4081/ejh.2025.4172. Eur J Histochem. 2025. PMID: 39931952 Free PMC article.
-
TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.PLoS One. 2014 Feb 5;9(2):e86824. doi: 10.1371/journal.pone.0086824. eCollection 2014. PLoS One. 2014. PMID: 24505269 Free PMC article. Clinical Trial.
-
Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.Eur Urol Focus. 2018 Dec;4(6):818-824. doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11. Eur Urol Focus. 2018. PMID: 28753864 Free PMC article.
-
Recurrent gene fusions in prostate cancer: their clinical implications and uses.Curr Urol Rep. 2013 Jun;14(3):214-22. doi: 10.1007/s11934-013-0321-1. Curr Urol Rep. 2013. PMID: 23625457 Review.
References
-
- Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8. - PubMed
-
- Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882–8. - PubMed
-
- Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538–44. - PubMed
-
- Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG Fusion by Translocation or Interstitial Deletion Is Highly Relevant in Androgen-Dependent Prostate Cancer, But Is Bypassed in Late-Stage Androgen Receptor-Negative Prostate Cancer. Cancer Res. 2006;66:10658–63. - PubMed
-
- Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396–400. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical